載入...

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist

BACKGROUND: Anti(α)-programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy fails to provide durable clinical benefit for most patients with carcinoma. Recent studies suggested that strategies to reduce immunosuppressive cells, promote systemic T-cell responses and lymphocyte tr...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Immunother Cancer
Main Authors: Knudson, Karin M, Hicks, Kristin C, Ozawa, Yohei, Schlom, Jeffrey, Gameiro, Sofia R
格式: Artigo
語言:Inglês
出版: BMJ Publishing Group 2020
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7204804/
https://ncbi.nlm.nih.gov/pubmed/32303618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000493
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!